Why people mistrust the biopharma industry and what to do about it

By Karen Taylor, Director, and Maria João Cruz, PhD, Assistant Research Manager, Deloitte Centre for Health Solutions

2021-05-07_18-08-54

Trust is critical for the biopharma industry, from influencing their chances of gaining and maintaining customers to their ability to recruit talent. Consumer’s trust in biopharma also gives the industry the incentive to innovate to provide life-saving therapies. Yet, biopharma still ranks as one of the least trusted industries, even though consumer polls show that the COVID-19 pandemic has helped improved trust. In January 2021, Deloitte’s US and UK Centres for Health Solutions conducted consumer research, using digital focus group discussions in four countries (the US, UK, India and South Africa) seeking to answer crucial questions around consumer trust in pharma. This week marks the launch of our research report, Overcoming biopharma’s trust deficit: Why people mistrust the biopharma industry – and what to do about it, and this blog highlights our take on the report and what companies can do to build and maintain trust.

Continue reading

Posted on 07/05/2021 | 0 Comments

How MedTech companies will drive the future of health

By Karen Taylor, Director, Centre for Health Solutions and Michel De Ridder, Partner, Deloitte Belgium, Regulatory compliance

Banner image-30-04

Last week my colleague Michel De Ridder and I participated in the annual MedTech Europe Forum 2021, where we delivered a presentation on our Deloitte Centre for Health Solutions research report 'Predicting the future of healthcare and life sciences in 2025: The future unmasked'. Our focus was on our sixth prediction 'MedTech and the IOMT are crucial drivers of value-based care'. However, we also discussed the implications of findings in our November 2020 research paper, ‘Winning in the future of MedTech’, underpinned by our global campaign on the Future of Health.i Following our presentation, we ran an ‘Ask the expert session’ to discuss emerging issues in relation to IP management. This week’s blog highlights the main themes that we discussed and explores the implications for MedTech companies’ role in the future of health. 

Continue reading

Posted on 30/04/2021 | 0 Comments

Intelligent drug launch and commercial: Optimising value through AI

By Dr. Maria João Cruz, PhD, Assistant Research Manager, Deloitte Centre for Health Solutions

April 23

This week marks the launch of the fifth report in our Intelligent biopharma series, which highlights the role of artificial intelligence (AI) in accelerating and driving digital transformation across the biopharma value chain. This report, Intelligent drug launch and commercial: Optimising value through AI, focuses on how companies can use AI to radically change and improve drug launches and their commercial models. The report also reflects on the challenges and disruptions caused by the COVID-19 pandemic and the response of commercial teams, including adapting new marketing and engagement channels to meet the needs of the different stakeholders.

Continue reading

Posted on 23/04/2021 | 0 Comments

Thriving after COVID-19: building an adaptable and resilient healthcare workforce

By Karen Taylor, Director Deloitte Centre for Health Solutions

Global healthcare outlook 2Deloitte’s, 2021 global health care outlook: Accelerating industry change, explores the six critical foundational shifts driving change in the health care sector. These shifts, which have been exacerbated by the COVID-19 pandemic, comprise consumers and the human experience; care model innovation; digital transformation and interoperable data; socio-economic shifts; public-private collaborations; and the future of work and talent. How governments understand and respond to these issues will shape their ability to navigate through recovery and thrive post-pandemic.  Over the next couple of months, as part of our blog series, we will examine each shift in turn. This week’s blog considers the future of work and talent, starting with the challenges pre-pandemic, the impact of the pandemic and need for adaptable and resilient workforce for the future. 

Continue reading

Posted on 16/04/2021 | 0 Comments

The role of genomics in shaping the UK’s public health response to COVID-19

By Emily May, Research Analyst, Deloitte Centre for Health Solutions

Genomes

In March 2020, the UK government established the COVID-19 Genomics UK Consortium (COG-UK) with an initial remit to contribute to the UK’s response to the COVID-19 pandemic by sequencing the SARS-CoV-2 genomes, identifying new variants of the virus, and combining this with clinical information to inform public health actions and policy decisions.1 To mark its first anniversary we explore some of the critical breakthroughs arising from COG-UK’s genomics research and how this is paving the way for a future in which genomics applications are fully integrated into public health.

Continue reading

Posted on 09/04/2021 | 0 Comments

Integrated Care Systems – establishing a patient centric health and care system

By Catherine Skilton, UK Public Sector Lead Partner for Integrated Care Systems and ConvergeHEALTH, Deloitte’s healthcare software products business

Patient care

The shift towards a digital-first healthcare system has accelerated during the COVID-19 pandemic, demonstrating that, given the opportunity for better access, people will engage in new ways with their health and wellbeing services. However, while many individuals have developed a greater awareness of their health and taken meaningful steps to improve it, the pandemic has exposed, and potentially increased inequalities in health outcomes due, in part, to inequalities in access to the technologies, connectivity, and digital and/or health literacy needed to improve outcomes equitably. Moreover, for some individuals improving health and wellbeing may not be their top priority, so new ways of engaging people, grounded in behavioural science, are required to optimise engagement with different segments of the population.

Continue reading

Posted on 01/04/2021 | 0 Comments

2021 global health care outlook: COVID‑19 created challenges, continues to accelerate changes

By Dr. Stephanie Allen, Deloitte Global Health Care sector leader, Deloitte Australia

Blog banner

Every year Deloitte produces a report exploring the outlook for the healthcare  sector. This year’s report, 2021 global health care outlook: Accelerating industry change explores the foundational shifts arising from and being exacerbated by COVID-19’s spread. Examples include consumers’ increasing involvement in health care decision-making; the rapid adoption of virtual health and other digital innovations; the push for interoperable data and data analytics use; and unprecedented public-private collaborations in vaccine and therapeutics development. Amid these dynamics, governments, health care providers, payers, and other stakeholders around the globe are being challenged to quickly pivot, adapt, and innovate. This week’s blog repurposes a blog by Stephanie Allen, our Deloitte Global Health Care sector leader, Deloitte Australia, which appeared first on our US Center for Health solutions Health Forward Blog site.

Continue reading

Posted on 26/03/2021 | 0 Comments

Start-up nation: The Future of Medtech is underway in Israel

By Glenn Snyder, principal, MedTech Practice leader, Deloitte Consulting LLP, and Arod Balissa, manager, Deloitte Catalyst | Tel Aviv

Cover

As we highlight in the six prediction of our report ‘The future unmasked, predicting the future of healthcare and life sciences in 2025’, MedTech companies have a critical role in driving the future of health, using transformative technology to enhance products and services, enabling 4P medicine and driving value-based care. Companies are also beginning to develop sophisticated data analytics capabilities and work more closely with end users to leverage AI and robotic technologies to improve patient outcomes. This week, we are sharing a blog by Glenn Snyder, Deloitte’s US MedTech Practice leader and Arod Balissa a manager at the Tel Aviv Deloitte Catalyst, in which they explore how MedTech is transforming health and care in Israel.

Continue reading

Posted on 19/03/2021 | 0 Comments

International Women’s Day: COVID-19’s impact on working women and how employers can help

By Krissie Ferris, Research Analyst, Deloitte Centre for Health Solutions, and Shivani Maitra, Partner, Human Capital, Life Sciences and Health Care

International womens banner image
Monday 8th March was International Women’s Day (IWD), celebrating the social, economic, cultural, and political achievements of women. The day also marked a call to action for accelerating women's equality.1 It also recognised that while the COVID-19 pandemic has had a detrimental impact on society as a whole, its impact has increased a number of pre-existing gender inequalities. Specifically, research suggests women are twice as likely as men to have lost their jobs, more likely to have been furloughed and have also been required to take on additional caring responsibilities.2 Women are also more likely work in industries that have been severely impacted by the COVID-19 outbreak.3 The theme of this year’s IWD is #ChooseToChallenge and in this week’s blog we explore how the voice of women can be used to challenge work and employment inequalities and create a fairer society.

Continue reading

Posted on 12/03/2021 | 0 Comments

The impact of COVID-19 in biopharma: Breaking through barriers to digitization

By Leena Gupta, manager, Deloitte Center for Health Solutions, Deloitte Services, LP

Hexagons

Next week will mark a full year since the WHO declared COVID-19 a pandemic. Since then, over 116 million cases have been reported globally and around 2.6 million people have lost their lives.1 In addition to its mounting human and societal impact, COVID-19 has significantly impacted most businesses and sectors, including the biopharmaceutical (biopharma) industry. This week, we share a blog by our colleague Leena Gupta, Manager at the US Center for Health Solutions, which explores how the pandemic has impacted biopharma’s various functions across the value chain and the strategies that have been adopted to help the industry respond and, ultimately, thrive. While Leena’s blog and research focussed on primarily on US policies, there are wider lessons that all geographies could benefit from. Over to Leena.

Continue reading

Posted on 05/03/2021 | 0 Comments

Accessing cell and gene therapies – meeting the needs of rare disease patients

By Lukasz Kaczynski, Senior Manager, Monitor Deloitte Switzerland, and Patricia Gee, Director, Monitor Deloitte Switzerland

Banner

February 28 2021 is the 14th International Rare Disease Day. To mark the occasion communities from across the world come together to raise awareness among the public and policy makers about rare diseases and their impact on the lives of patients and families.1 Rare diseases are heterogeneous in nature, and geographically disparate, few are preventable or curable, most are chronic and progressive, and many are life-threatening. While there is no universal definition of rare diseases, in 2019, a comprehensive research study of the Orphanet database2 estimated that there are some 6,200 rare diseases affecting some 3.5 to 5.9 per cent of the global population, a total of approximately 263 to 446 million people. Around 72 per cent of these rare diseases are genetic with 70 per cent starting in childhood.3  Today, transformative cell and gene therapies (CGTx), with the potential to address and often eliminate the underlying cause of a genetic disease, bring hope to patients and families affected by rare diseases.

Continue reading

Posted on 26/02/2021 | 0 Comments